Biotest increases sales in the first half of 2024 by 35% to Euro 372 million – Biotech Investments

PRESS RELEASE

Biotest increases sales in the first half of 2024 by 35% to € 372 million

• EBIT increased to € 78.4 million
• FDA approval of Yimmugo^® received in June 2024
• FDA certification of the BNL production facility in Dreieich
• Strategic distribution agreement with Kedrion is expected to generate revenues of more than
  $1 billion for Biotest during the 7-year term

Dreieich, 30 July 2024. In the first half of the 2024 financial year, the Biotest Group generated revenue of € 372.0 million. This corresponds to growth of 35.1% compared to the revenue of € 275.3 million generated in the same period of the previous year. Product revenue grew by € 13.4 million, or 4.8%, to € 273.7 million. In addition, revenue from technology disclosure and development services for Grifols, S.A., as part of the technology transfer and licensing agreement amounted to € 98.3 million.

Compared to the prior-year period, consolidated EBIT grew to € 78.4 million in the first six months of the 2024 financial year (prior-year period: € 19.8 million). This growth mainly reflected the earnings effect from technology disclosure and development services as part of the technology and licence agreement with Grifols, S.A., amounting to € 86.0 million (prior-year period: € 1.9 million).

Earnings before interest, taxes, depreciation and amortization (EBITDA) amounted to € 100.1 million in the first six months of the 2024 financial year after € 37.5 million in the first six months of the previous year.

The Biotest Group’s earnings after taxes (EAT) rose to € 39.1 million in the first half of 2024 (prior year period: € 1.7 million). This results in earnings per ordinary share of € 0.98 after € 0.03 in the first half of 2023.

Biotest will publish the full figures for the first six months of the 2024 financial year on August 06, 2024. A separate invitation will be sent out for the conference call to be held on the same day.

About Biotest

Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,600 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange. Since May 2022, Biotest is part of the Grifols Group, Barcelona, Spain (www.grifols.com).

Biotest AG will also distribute official press releases via X with immediate effect. You can find us at: https://twitter.com/BiotestAG

IR contact

Dr Monika Baumann (Buttkereit)
Phone: +49-6103-801-4406
Mail: ir@biotest.com

PR contact

Dirk Neumüller
Phone: +49-6103-801-269
Mail: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201
Preference shares: securities’ ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.